The Rationale for Druggability of CCDC6-tyrosine Kinase Fusions in Lung Cancer

Molecular Cancer - United Kingdom
doi 10.1186/s12943-018-0799-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Tyrosine Kinase Inhibitors in Lung Cancer

Hematology/Oncology Clinics of North America
OncologyHematology
2012English

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

Current Oncology
Oncology
2012English

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

Current Oncology
Oncology
2012English

Elucidating the Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer Patients

Canadian Journal of Biotechnology
2017English

Non-Small Cell Lung Cancer-Small Cell Lung Cancer Transformation as Mechanism of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

2020English

Evaluation of a Tyrosine Kinase Peptide Microarray for Tyrosine Kinase Inhibitor Therapy Selection in Cancer

Experimental & Molecular Medicine
2016English

Receptor Tyrosine Kinase Expression of Circulating Tumor Cells in Small Cell Lung Cancer

Oncoscience
Cancer ResearchOncology
2015English

Defining the Role of Tyrosine Kinase Inhibitors in Early Stage Non-Small Cell Lung Cancer

Journal of Cancer
Oncology
2015English

Development of Crizotinib, a Rationally Designed Tyrosine Kinase Inhibitor for Non-Small Cell Lung Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy